SHIGERU AG invested in Capretto ehf, a University of Iceland-affiliated biotech company focused on developing antibiotic lipids.

Target Information

In November 2021, SHIGERU AG participated in a Series A funding round for Capretto ehf, a biotechnology venture affiliated with the University of Iceland. Capretto ehf is focused on developing medical devices and is engaged in research and development concerning the pharmacological activity of monocaprin and monolaurin, functioning as antibiotic lipids.

The company's innovative approach combines academic research with practical applications in the healthcare sector, capitalizing on the natural antimicrobial properties of these compounds to potentially enhance infection control and treatment strategies.

Industry Overview

The biotechnology industry in Iceland has seen significant advancements in recent years, driven by strong academic institutions and a growing interest in biopharmaceut